VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 25, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that Dr. Anthony Tolcher, one of the Company's Clinical Advisory Board Members, will be one of the speakers in a Major Symposium at the American Association for Cancer Research ("AACR") Annual Meeting taking place April 12-16, 2008 in San Diego. Dr. Tolcher will discuss the translation of preclinical studies to clinical trials for compounds targeting chemokine receptors and metastasis. Chemokine Therapeutic's CTCE-9908 drug candidate will be highlighted as one of the leading agents targeting CXCR4 used to reduce metastasis and cancer growth.
